Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CEO of China Drug Maker Jumps to Death Amid Bribery Probe

By Drug Discovery Trends Editor | May 20, 2014

The chief executive of a Chinese drug company has jumped to his death, the company said Monday. State media said he was under investigation on suspicion of taking bribes.
 
Sanjing Pharmaceutical Co. Ltd. said Liu Zhanbin jumped Sunday from a third-floor bathroom window in a hospital where he was receiving medical treatment under the supervision of court guards.
 
Sanjing said the company has appointed an interim CEO and that Liu’s death would have no impact on its operations.
 
The government’s China News Service and the Communist Party newspaper People’s Daily said Liu was under investigation on suspicion of taking bribes. They gave no details of the investigation.
 
The Chinese government has launched a sweeping investigation of drug companies as part of efforts to improve health care and rein in drug prices.
 
Doctors and hospitals in China’s state-run, poorly funded health system routinely accept informal payments from patients and suppliers of drugs and medical goods.
 
Hospitals also raise money by adding surcharges to drug prices and assigning employees sales quotas. That encourages the overuse of expensive drugs or procedures.
 
Last Wednesday, the public security ministry announced that a British executive of GlaxoSmithKline has been accused of leading a sprawling scheme to bribe doctors and hospitals to use its drugs. It said the case has been turned over to prosecutors.
 
Date: May 19, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE